A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Alopecia Areata - 12 years of age and older

Exclusion Criteria:

- JAK Inhibitor use

Conditions & Interventions

Conditions:
Dermatology (Skin, Hair & Nails)
Keywords:
Alopecia Areata

More Information

Description: Ritlecitinib (LITFULO™, PF-06651600) 50 mg daily is currently approved for people 12 years of age and older to treat severe alopecia areata (hair loss). Ritlecitinib 100 mg will be compared to Ritlecitinib 50 mg to find out if a larger daily dose is safe and can improve regrowth of hair. The study will last about 57 weeks and will have up to 9 visits. Everyone will get one of the two doses of the study drug.
Study Contact: Jaime Nugent - speck007@umn.edu
Principal Investigator: Maria Hordinsky
Phase: PHASE3
IRB Number: STUDY00025039